CDKN2A and melanoma: This genetic panel testing has been useful in previous work in supporting molecular factors for prognostication and risk stratification in melanoma patients.28 As expected based on prior work,29 the most commonly mutated genes in our cohort were TERT, BRAF, NRAS, and CDKN2A.